CNBC’s Jim Cramer delivers his daily Mad Dash.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter ...
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.
Explore advancements in biotechnology, from gene editing's ethical dilemmas to synthetic biology's commercial potential and ...
Zacks Investment Research on MSN
Will strength in biotechnology unit continue to drive DHR's growth?
Danaher Corporation’s DHR Biotechnology segment continues to be a major contributor to its growth. In the first quarter of ...
MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...
From quantum computing and aerospace to biotechnology, artificial intelligence, clean energy and restaurant innovation, the ...
Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...
In a joint letter to Treasurer Jim Chalmers, 17 industry organisations called for consultation on two RDTI changes announced ...
In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...
Mount Sinai physician joins Northwell as chief biotechnology officer, leading biotech strategy and intellectual property at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results